Fig. 6

MET amplification and protein overexpression predicted the sensitivity to MET inhibitors. a The IC50 values of NZ001, PF-04217903 and XL184 in a panel of HCC cell lines were determined by CCK-8 assay. b The association of MET gene copy number in HCC cell lines and MET/P-MET protein expression levels detected by IHC in subcutaneous tumor tissues with the sensitivity to NZ001 treatment in HCC cell lines. c Comparison of tumor growth rates in subcutaneous implantation models of MHCC-97H and Huh7 cells after treatment with different dose of NZ001 (either 10 or 30 mg/kg daily for 14 days). Tumor volumes were measured and recorded every 3 days from initial treatment to tumor harvest. d Tumor growth inhibition (TGI) was measured at the end of the experiment. e-g Effects of NZ001 on proliferation, apoptosis and angiogenesis of MHCC-97H and Huh7 xenografts determined by IHC. h Body weights were measured and recorded from initial treatment to tumor harvest. i Comparison of the inhibitory effects of NZ001 and sorafenib in MHCC-97H xenografts models (30 mg/kg of NZ001 or sorafenib for 14 days). Tumor volumes were measured and recorded every 3 days from initial treatment to tumor harvest. Data are shown as the mean ± SD. Significant differences were determined using one-way ANOVA. *: P < 0.05; **: P < 0.01; NS: No Significance